FORM 4

UNITED STATES SECU

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Martini Jeffrey S					2. Issuer Name and Ticker or Trading Symbol PALVELLA THERAPEUTICS, INC. [PVLA]						LA (Ch	5. Relationship of Reporting Pers (Check all applicable) Director Officer (give title			10% Ow Other (s	ner	
(Last) (First) (Middle) C/O PALVELLA THERAPEUTICS, INC. 125 STRAFFORD AVENUE, SUITE 360					3. Date of Earliest Transaction (Month/Day/Year) 12/13/2024						below) below) Chief Scientific Officer						
(Street) WAYNE (City)			19087	4.	. If Ame	endment, [Oate o	of Original Fi	led (N	Month/Da	y/Year)	Line	Form fil	led by One led by More	Repo	(Check Appl rting Person One Report	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				е	Execution Date		Code (Instr.		ties Acquir d Of (D) (Ins	ed (A) or str. 3, 4 and	Beneficia Owned Fo	s Illy ollowing	Form:	: Direct I Indirect E str. 4) C	7. Nature of ndirect Beneficial Dwnership		
								Code	v	Amount	Amount (A) or (D)		Reported Transacti (Instr. 3 a	tion(s)			Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any		Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		piration ite	Title	Amount or Number of Shares		(Instr. 4)	J.11(3)		
Stock Option (right to buy)	\$13.6	12/13/2024		A		126,416		(1)	12/	/13/2034	Common Stock	126,416	\$0	126,41	6	D	

Explanation of Responses:

1. The stock options will vest in equal monthly tranches over 48 months

Kathleen A. McGowan, Attorney-in-Fact

12/17/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.